retatrutide triple agonist obesity phase 2 trial for Obesity: Weight-Loss Data When the Breakthrough Obesity G-Agonist

Use of blockbuster anti-obesity drugs like Wegovy and Zepbound is growing, with about 1 in 8 adults in the U.S

It enhances glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying key mechanisms for glucose control

In a 16-week placebo-controlled study, participants using SLENDACOR alongside diet and exercise lost an average of 12 pounds and achieved results that were 6 times greater than diet and exercise alone. MyGLP-1 ProClinical delivers a comprehensive, stimulant-free approach to weight management and metabolic health

Research & Study Insights

DduB2B

Compare 5 ways to save on Lamictal XR with or without insurance